Evidence map›Paper›PMID 33128130›Full record

ReviewCurrent neurology and neuroscience reports2020

Central Nervous System Manifestations Associated with COVID-19.

Afshin A Divani, Sasan Andalib, José Biller, Mario Di Napoli, Narges Moghimi, Clio A Rubinos, Christa O'Hana Nobleza, P N Sylaja, Michel Toledano, Simona Lattanzi and 4 more

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 64 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Afshin A DivaniDepartment of Neurology, School of Medicine, University of New Mexico, Albuquerque, NM, USA. adivani@gmail.com.
Sasan AndalibDepartment of Neurology, School of Medicine, University of New Mexico, Albuquerque, NM, USA.
José BillerDepartment of Neurology, Loyola University, Stritch School of Medicine, Maywood, IL, USA.
Mario Di NapoliDepartment of Neurology and Stroke Unit, San Camillo de' Lellis District General Hospital, Rieti, Italy.
Narges MoghimiDepartment of Neurology, School of Medicine, University of New Mexico, Albuquerque, NM, USA.
Clio A RubinosDepartment of Neurology, University of North Carolina, Chapel Hill, NC, USA.
Christa O'Hana NoblezaDepartment of Neurology, The University of Mississippi Medical Center, Jackson, MS, USA.
P N SylajaSree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, India.
Michel ToledanoDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Simona LattanziNeurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy.
Louise D McCulloughDepartment of Neurology, McGovern Medical School, The University of Texas at Houston, Houston, TX, USA.
Salvador Cruz-FloresNeurology Department, Texas Tech Health University, Health Sciences Center, El Paso, El Paso, TX, USA.
Michel TorbeyDepartment of Neurology, School of Medicine, University of New Mexico, Albuquerque, NM, USA.
M Reza AzarpazhoohDepartments of Clinical Neurological sciences, Western University, London, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewCoronavirus disease 2019 (COVID-19) has become a global health crisis of our time. The disease arises from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that binds to angiotensin-converting enzyme 2 (ACE2) receptors on host cells for its internalization. COVID-19 has a wide range of respiratory symptoms from mild to severe and affects several other organs, increasing the complexity of the treatment. There is accumulating evidence to suggest that SARS-CoV-2 can target the nervous system. In this review, we provide an account of the COVID-19 central nervous system (CNS) manifestations. RECENT

findingsA broad spectrum of the CNS manifestations including headache, impaired consciousness, delirium, loss of smell and taste, encephalitis, seizures, strokes, myelitis, acute disseminated encephalomyelitis, neurogenic respiratory failure, encephalopathy, silent hypoxemia, generalized myoclonus, neuroleptic malignant syndrome and Kawasaki syndrome has been reported in patients with COVID-19. CNS manifestations associated with COVID-19 should be considered in clinical practice. There is a need for modification of current protocols and standing orders to provide better care for COVID-19 patients presenting with neurological symptoms.

Indexed as

BetacoronavirusCoronavirusCoronavirus InfectionsNervous System DiseasesPandemicsPneumonia, ViralCOVID-19HumansSARS-CoV-2CNS manifestationsCOVID-19Neurological manifestationsPandemicSARS-CoV-2Stroke

Identifiers

PMID33128130
PMCPMC7599061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.